Brand Name
Ahzantive
Generic Name
Aflibercept-Mrbb
View Brand Information FDA approval date: June 01, 2024
Classification: Vascular Endothelial Growth Factor Inhibitor
Form: Injection
What is Ahzantive (Aflibercept-Mrbb)?
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Brand Information
AHZANTIVE (aflibercept-mrbb)
1These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024
1 INDICATIONS AND USAGE
AHZANTIVE is indicated for the treatment of:
1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)